Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.77B P/E - EPS this Y -151.90% Ern Qtrly Grth -
Income -137.24M Forward P/E -8.01 EPS next Y 3.00% 50D Avg Chg -8.00%
Sales 295.39M PEG - EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 3.90 EPS next 5Y - 52W High Chg -30.00%
Recommedations 1.70 Quick Ratio 11.37 Shares Outstanding 142.61M 52W Low Chg 27.00%
Insider Own 13.68% ROA -8.70% Shares Float 123.16M Beta 1.39
Inst Own 84.55% ROE -11.33% Shares Shorted/Prior 10.50M/9.41M Price 27.56
Gross Margin -36.12% Profit Margin -46.46% Avg. Volume 688,159 Target Price 39.69
Oper. Margin -70.46% Earnings Date Aug 6 Volume 498,608 Change -2.68%
About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc. News
05/11/24 The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
05/09/24 Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)
05/08/24 Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
05/07/24 Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts
05/07/24 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
05/01/24 Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
04/29/24 Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
04/09/24 Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
03/29/24 Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
03/28/24 Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
03/19/24 Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%
02/28/24 Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
02/27/24 Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results
02/27/24 Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
02/27/24 Denali Therapeutics Announces $500 million Private Placement Equity Financing
02/27/24 Denali, fresh off study setback, gets $500M lift
02/16/24 UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal
02/16/24 ALS drug from Denali, Sanofi falls short in mid-stage study
02/07/24 Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
02/01/24 Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
DNLI Chatroom

User Image MaverikIT Posted - 1 week ago

@DonCorleone77 @net0trader @IsabellaDC @RonIsWrong @Cash4freedom @Wigglyick @Im_not_Mr_Lebowski $KD $ELAN $AOSL $DNLI ....

User Image stockpivot Posted - 1 week ago

$DNLI Profit Booked

User Image MaverikIT Posted - 1 week ago

@DonCorleone77 @net0trader @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @IsabellaDC @CycleTrade $ANET $AOSL $DNLI

User Image Tomppa Posted - 1 week ago

$DNLI great to be back

User Image Stock_Titan Posted - 1 week ago

$DNLI Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-first-quarter-2024-financial-results-and-imw9kcpng47j.html

User Image Daniyo7 Posted - 1 week ago

$DNLI time to go back to high numbers 💪!! Let's goo up to 22$+ 🚀🔥 🌟

User Image Shimy Posted - 1 week ago

$DNLI man, so many crappy/scammy biotechs out there, this one is as solid as they get but gets no love. Shouldve loaded the boat at sub $15 but $17 is totally fine. Baker bros are in this and theyre never wrong right 😂

User Image Stock_Titan Posted - 2 weeks ago

$DNLI Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial https://www.stocktitan.net/news/DNLI/denali-therapeutics-announces-completion-of-enrollment-for-regimen-g-9ak0xptp8h99.html

User Image Tadstonk Posted - 04/24/24

$DNLI just average down. This is silly for a company with 1.5 billion in cash and on cusp of approval for 310 and ERT platform. Gift!!!!!

User Image stuntman9883 Posted - 04/18/24

$DNLI https://vm.tiktok.com/ZGeHAedj9/ huge cash pile

User Image insiderbuyingselling Posted - 04/18/24

$DNLI new insider selling: 1666 shares. http://insiderbuyingselling.com/?t=DNLI

User Image Tadstonk Posted - 4 weeks ago

$DNLI never been more bullish

User Image stuntman9883 Posted - 1 month ago

$DNLI https://vm.tiktok.com/ZGeu4j7hc/ Started a position here

User Image Capes Posted - 1 month ago

$JTAI $RANI $DNLI $ICU $KITT

User Image BobBijawk Posted - 03/23/24

$IBRX next on radar for biotech making a potential first in class compound/compounds $bmea essentially treating the cellular mechanism in which diabetic individuals require insulin. This drug has shown long lasting no side effects reducing or eliminating need for insulin over time. Appears to be giving nwar complete remissions in early stage. $dnli will provide the first approved treatment for hunters disease. Expect many partnerships with their brain blood barrier tech . $Igms a igm antibody pipeline with the efficacy of car t and a fraction of cost and production time . Sanofi is a partner. $Tara production of a BCG like vaccine that is utilizing a strep strain much easier and more efficient than BCG. Each one of the forementionwed are trailblazing a spot by themselves like Anktiva.

User Image DonCorleone77 Posted - 03/22/24

$DNLI Denali Therapeutics files to sell 29.29M shares of common stock for holders

User Image BobBijawk Posted - 2 months ago

$IBRX I am also watching $bmea reason being they are carving a niche in the diabetes market if approved they stand to be the only drug of its kind and it has durable response and is potentially a long lasting cure of one of the major causes of type two diabetes. Just like ibrx is carving out a place in late stage so are they. Just like $dnli could be carving a spot and $igms could be carving a spot. The aforementioned are many years away so for now I'm weighted ibrx heavy. 15k shares and adding.

User Image ForestFoxes Posted - 2 months ago

This article list four companies ... $AVXL $ANVS $BIVI $DNLI and $BIIB are among them. Source: https://www.nasdaq.com/articles/four-biotech-stocks-for-parkinsons-disease-awareness-month

User Image Tadstonk Posted - 02/29/24

$DNLI Rare disease day. We lose boys every day to MPS while FDA does NOTHING. Special place in hell for these heartless govt asses.

User Image Fullratio Posted - 02/28/24

$DNLI debt is 95% less than its equity: https://fullratio.com/stocks/nasdaq-dnli/denali-therapeutics

User Image Monkey_Banana_Genius Posted - 02/28/24

$DNLI huge breakout on volume yesterday

User Image swingingtech Posted - 02/28/24

$DNLI $BIIB $PBYI https://wallstreetwaves.com/denalis-dnli-q4-earnings-miss-pipeline-in-focus-stock-up/

User Image tradingtwenty Posted - 02/27/24

Top 5 stock gainers today that have trended in the past 24 hours: $JANX 229.47% 🔥 $VKTX 121.02% $CXAI 81.94% $DNLI 38.25% $BBAI 38.15% Link: https://tradingtwenty.com/dashboard/trending/past

User Image HippoCritical Posted - 02/27/24

$DNLI yeeee

User Image ThaDinkels Posted - 02/27/24

$JANX $VKTX $DNLI man all the biotechs are having a day! Looks like $IMNN is loading up to be the next big break out! FDA Ind approval news should be out this quarter! Would be a hell of a time for that news to drop with all the bio techs blowing up right now!

User Image Groov Posted - 02/27/24

$DNLI $IBRX good call BobBj

User Image TheMatrixOracle Posted - 02/27/24

$DNLI Couple years back this was 80+, can it get there again?

User Image MMCT Posted - 02/27/24

$DNLI missed this today 🥲🥲🥲🥲 Was in my WL

User Image Vegas1 Posted - 02/27/24

$DNLI bingo!!!!!!!!

User Image TheMatrixOracle Posted - 02/27/24

$DNLI Great week for therapeutics.

Analyst Ratings
Wedbush Outperform May 8, 24
Stifel Hold May 8, 24
HC Wainwright & Co. Buy May 8, 24
UBS Buy Apr 9, 24
Goldman Sachs Buy Feb 29, 24
HC Wainwright & Co. Buy Feb 28, 24
Wedbush Outperform Feb 28, 24
HC Wainwright & Co. Buy Feb 22, 24
Citigroup Buy Dec 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SATO VICKI L Director Director Jan 16 Sell 18.42 1,666 30,688 123,041 01/18/24
Ho Carole Chief Medical Office.. Chief Medical Officer Jan 10 Sell 19.02 4,668 88,785 147,794 01/12/24
Watts Ryan J. President and CEO President and CEO Jan 09 Sell 19.78 7,818 154,640 2,268,363 01/11/24
Ho Carole Chief Medical Office.. Chief Medical Officer Jan 05 Sell 19.43 9,972 193,756 198,777 01/09/24
Krognes Steve E. Director Director Jan 05 Sell 19.43 3,208 62,331 142,591 01/09/24
Schuth Alexander O. COFO and Secretary COFO and Secretary Jan 05 Sell 19.43 9,972 193,756 539,307 01/09/24
Watts Ryan J. President and CEO President and CEO Jan 05 Sell 19.43 17,483 339,695 2,276,181 01/09/24
SATO VICKI L Director Director Dec 15 Sell 23.39 1,666 38,968 124,707 12/18/23
SATO VICKI L Director Director Nov 15 Sell 19.13 1,666 31,871 126,373 11/16/23
SATO VICKI L Director Director Oct 16 Sell 20.66 1,666 34,420 128,039 10/18/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Aug 23 Sell 23.17 2,522 58,435 518,989 08/25/23
Ho Carole Chief Medical Office.. Chief Medical Officer Aug 23 Sell 23.22 2,522 58,561 182,809 08/25/23
Krognes Steve E. Director Director Aug 21 Sell 22.60 1,419 32,069 145,799 08/23/23
SATO VICKI L Director Director Aug 15 Sell 24.30 1,666 40,484 131,371 08/17/23
Ho Carole Chief Medical Office.. Chief Medical Officer Aug 14 Sell 23.79 2,768 65,851 182,809 08/16/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Aug 14 Sell 23.67 2,772 65,613 518,989 08/16/23
Watts Ryan J. President and CEO President and CEO Aug 10 Sell 25.03 2,526 63,226 2,239,913 08/14/23
Watts Ryan J. President and CEO President and CEO Aug 10 Option 0.68 2,526 1,718 2,242,439 08/14/23
Ho Carole Chief Medical Office.. Chief Medical Officer Aug 10 Sell 24.15 2,857 68,997 185,577 08/14/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Aug 10 Sell 24.18 2,853 68,986 521,761 08/14/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Jul 17 Sell 29.81 19,702 587,317 518,989 07/19/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Jul 17 Option 5.28 10,000 52,800 538,691 07/19/23
SATO VICKI L Director Director Jul 17 Sell 29.60 1,666 49,314 133,037 07/19/23
SATO VICKI L Director Director Jun 28 Sell 29.77 1,666 49,597 134,703 06/30/23
Watts Ryan J. President and CEO President and CEO Apr 20 Option 0.68 25,000 17,000 2,264,713 04/24/23
Watts Ryan J. President and CEO President and CEO Apr 20 Sell 25.08 25,000 627,000 2,239,913 04/24/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Apr 12 Sell 25.04 10,000 250,400 528,691 04/14/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Apr 12 Option 5.28 10,000 52,800 533,589 04/14/23
Krognes Steve E. Director Director Feb 13 Sell 30.10 2,119 63,782 143,002 02/15/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Feb 13 Sell 30.09 3,497 105,225 528,691 02/15/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Feb 13 Option 0.68 25,000 17,000 524,902 02/15/23
Watts Ryan J. President and CEO President and CEO Feb 13 Sell 30.09 33,815 1,017,493 2,239,913 02/15/23
Watts Ryan J. President and CEO President and CEO Feb 13 Option 0.68 25,000 17,000 2,264,913 02/15/23
Ho Carole Chief Medical Office.. Chief Medical Officer Feb 10 Sell 29.95 3,366 100,812 184,285 02/14/23
Watts Ryan J. President and CEO President and CEO Feb 09 Sell 29.85 28,433 848,725 2,229,031 02/13/23
Watts Ryan J. President and CEO President and CEO Feb 09 Option 0.68 25,000 17,000 2,254,031 02/13/23
Ho Carole Chief Medical Office.. Chief Medical Officer Jan 05 Sell 28.56 4,087 116,725 178,913 01/09/23
Krognes Steve E. Director Director Jan 05 Sell 28.44 2,970 84,467 146,498 01/09/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Jan 05 Sell 28.44 2,636 74,968 497,173 01/09/23
Watts Ryan J. President and CEO President and CEO Jan 05 Sell 28.44 4,800 136,512 2,223,664 01/09/23
Ho Carole Chief Medical Office.. Chief Medical Officer Jan 03 Sell 28.69 2,913 83,574 175,500 01/05/23
Schuth Alexander O. COFO and Secretary COFO and Secretary Jan 03 Sell 28.7 2,912 83,574 149,828 01/05/23
Watts Ryan J. President and CEO President and CEO Jan 03 Sell 28.73 5,029 144,483 2,213,464 01/05/23
Tessier-Lavigne Marc Director Director Nov 23 Sell 30.48 20,000 609,600 1,870,356 11/28/22
Tessier-Lavigne Marc Director Director Sep 28 Sell 30.91 20,000 618,200 1,910,356 09/30/22
Tessier-Lavigne Marc Director Director Aug 23 Sell 32.02 20,000 640,400 1,930,356 08/25/22
Ho Carole Chief Medical Office.. Chief Medical Officer Aug 23 Sell 31.98 2,424 77,520 170,663 08/25/22
Watts Ryan J. President and CEO President and CEO Aug 19 Sell 33.22 2,404 79,861 2,202,993 08/23/22
Krognes Steve E. Director Director Aug 19 Sell 33.22 2,253 74,845 149,468 08/23/22
Schuth Alexander O. COFO and Secretary COFO and Secretary Aug 19 Sell 33.22 2,576 85,575 467,471 08/23/22